ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pembrolizumab

Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Urinary Bladder Neoplasms, led by 8 companies.

Drug pagePembrolizumab: every studyMany companies study it; this page follows only the 148 they lead. All 1,133 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 19, 2018148 company-led studies, 27 open or runningNext primary completion: Nov 20, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck13824 open or runningphase 4since Oct 19, 2018Feb 10, 2011Nov 20, 2026phase 3 · NCT04634877
Novartisits history only30 open or runningphase 2since May 15, 2019Dec 12, 2013none ahead
PDS Biotechnologyits history only20 open or runningphase 3since Jan 14, 2025Feb 5, 2020none ahead
AGO Researchits history only11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
EverNov Medicines (Zhuhai Hengqin)its history only10 open or runningphase 2since Dec 29, 2020Dec 29, 2020none ahead
Mediclinic Middle Eastits history only10 open or runningphase 2since Mar 14, 2019Mar 14, 2019none ahead
NovoCureits history only11 open or runningphase 3since Aug 13, 2024Aug 13, 2024Apr 2029phase 3 · NCT06556563
TiumBioits history only11 open or runningphase 2since Feb 20, 2023Feb 20, 2023Dec 2026phase 2 · NCT05784688

Also a collaborator on its studies: Eisai, Pfizer, Astellas Pharma, Novotech (Australia) Pty and Medidata Solutions.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 52 studies since Aug 23, 2018.

  1. Jul 6, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04956692 · 531 enrolled · United States, Brazil, France and more
  2. Aug 13, 2021Phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05008224 · 146 enrolled · United States, Australia, Canada and more
  3. Oct 28, 2021Phase 3 study in Ovarian NeoplasmsNCT05116189 · 643 enrolled · United States, Australia, Belgium and more
  4. Dec 20, 2021Phase 3 study in Endometrial NeoplasmsNCT05173987 · 280 enrolled · United States, Australia, Belgium and more
  5. Feb 4, 2022Phase 3 study in Colorectal NeoplasmsNCT05239741 · 100 enrolled · China
  6. Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06099782 · 147 enrolled · United States, Argentina, Australia and more
  7. Dec 11, 2025Phase 2 study in NeoplasmsNCT07302347 · 20 planned · Japan
  8. Aug 28, 2026Phase 4 study in NeoplasmsNCT07801027 · 150 planned
  9. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03833167 · “The study stopped due to futility”
  10. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03834493 · “The study stopped due to futility”
  11. Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT04191096 · “The study stopped due to futility”
  12. Oct 2, 2026Primary completion moved from 2026-11-06 to 2027-02-12Date moved laterphase 2 · +3 months · NCT03407144
  13. Oct 23, 2026Primary completion moved from 2026-07-31 to 2028-07-31Date moved laterphase 3 · +24 months · NCT03711032
  14. Nov 18, 2026Phase 2 study terminatedStudy stoppedNCT04428151 · “Business Reasons”

Ahead

  1. Nov 20, 2026Primary completion: phase 3 study in Endometrial NeoplasmsNCT04634877
  2. Jan 31, 2027Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT04241185
  3. May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT04380636
  4. May 27, 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT05173987

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The newest 60 of 138 Merck leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07801027Neoplasms4Not yet recruitingJan 31, 2030150
NCT07302347Neoplasms · Japan2RecruitingMar 30, 202920
NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2Active, not recruitingApr 9, 2025147
NCT05239741Colorectal Neoplasms · China3Active, not recruitingSep 19, 2028100
NCT05173987Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMay 27, 2027280
NCT05116189Ovarian Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMar 5, 2025643
NCT05008224Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedOct 11, 2023146
NCT04956692Carcinoma, Non-Small-Cell Lung · United States, Brazil, France and more3CompletedApr 4, 2023531
NCT04934722Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedOct 31, 2022186
NCT04924062Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedDec 15, 2022158
NCT04907227Prostatic Neoplasms · China3TerminatedAug 3, 202281
NCT04895358Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingApr 24, 2026342
NCT04882241Stomach Neoplasms · China3CompletedFeb 16, 2024120
NCT04875195Hodgkin Disease · United States, Brazil, Canada and more2CompletedDec 14, 202366
NCT04865289Endometrial Neoplasms · China3CompletedOct 2, 2023130
NCT04859582Stomach Neoplasms · China3WithdrawnNov 29, 20240
NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedSep 27, 2024563
NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedJan 27, 2025160
NCT04700124Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingOct 27, 2025808
NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedOct 29, 2024895
NCT04634877Endometrial Neoplasms · United States, Argentina, Austria and more3Active, not recruitingNov 20, 2026990
NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more3Active, not recruitingOct 28, 2027672
NCT04489888Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more4CompletedFeb 20, 2023101
NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more2TerminatedMay 31, 2024408
NCT04380636Lung Neoplasms · United States, Argentina, Canada and more3Active, not recruitingMay 5, 2027870
NCT04317066Lymphoma, B-Cell · Japan1CompletedApr 11, 20247
NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more3TerminatedAug 19, 2025480
NCT04241185Urinary Bladder Neoplasms · United States, Australia, Chile and more3Active, not recruitingJan 31, 2027520
NCT04221945Uterine Cervical Neoplasms · United States, Australia, Austria and more3CompletedJan 7, 20251,060
NCT04210115Esophageal Squamous Cell Carcinoma · United States, Argentina, Belgium and more3CompletedJan 21, 2026703
NCT04191096Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Austria and more3TerminatedOct 31, 20221,251
NCT04153565Mesothelioma · Japan1CompletedSep 21, 202219
NCT04123366Solid Tumors · United States, Argentina, Australia and more2CompletedJun 8, 2026333
NCT04003636Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedDec 15, 20221,069
NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAug 11, 2023422
NCT03950674Carcinoma, Non-Small-Cell Lung · Japan3CompletedMay 20, 201940
NCT03933449Esophageal Neoplasms · China3CompletedFeb 13, 2019123
NCT03924895Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJun 6, 2025595
NCT03924869Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3TerminatedJun 11, 2024448
NCT03924856Urinary Bladder Neoplasms · United States, Australia, Belgium and more3CompletedJan 26, 2026907
NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedOct 2, 2023842
NCT03881111Esophageal Neoplasms · China3WithdrawnMay 11, 20210
NCT03875092Carcinoma, Non-Small-Cell Lung · China3CompletedSep 30, 2020125
NCT03867084Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedMar 20, 2025959
NCT03850444Carcinoma, Non-Small-Cell Lung3CompletedSep 4, 2018262
NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMar 14, 2022793
NCT03834506Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedJun 20, 20221,030
NCT03834493Prostatic Neoplasms · United States, Argentina, Australia and more3TerminatedDec 12, 20221,244
NCT03833167Carcinoma, Squamous Cell · United States, Argentina, Australia and more3TerminatedJun 28, 2024450
NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more2CompletedOct 28, 2024611
NCT03783078Carcinoma, Merkel Cell · United States, Australia, Canada and more3CompletedFeb 15, 202255
NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedOct 11, 2023103
NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more3CompletedAug 26, 20241,367
NCT03765918Head and Neck Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJul 25, 2024714
NCT03725059Breast Neoplasms · United States, Australia, Belgium and more3Active, not recruitingJan 24, 20311,240
NCT03715205Carcinoma, Non-Small-Cell Lung · India4CompletedAug 21, 2024150
NCT03713593Carcinoma, Hepatocellular · United States, Australia, Canada and more3CompletedJun 21, 2022794
NCT03711032Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Austria and more3Active, not recruitingJul 31, 20281,397
NCT03675737Stomach Neoplasms · United States, Argentina, Australia and more3CompletedOct 3, 20221,579
NCT03665597Melanoma · Australia, South Africa, Spain and more1CompletedDec 4, 2023138

How it is read

Names in the registry

  • “Pembrolizumab”, 124 entries
  • “pembrolizumab”, 29 entries
  • “Pembrolizumab 200 mg”, 7 entries
  • “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
  • “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.